BiotechTubeBiotechTube
Home/MindWalk Holdings/Dr. Samantha Chen, Ph.D.
DS

Dr. Samantha Chen, Ph.D.

Chief Scientific Officer

MindWalk Holdings

Therapeutic Areas

NeurosciencePsychiatryNeurology

MindWalk Holdings Pipeline

DrugIndicationPhase
MW-101Major Depressive Disorder (MDD)Phase 2
MW-201Alzheimer's Disease (Agitation)Phase 1/2
MW-301Parkinson's Disease PsychosisPhase 1
MW-401Generalized Anxiety Disorder (GAD)Pre-clinical
MW-501Cognitive Impairment associated with Schizophrenia (CIAS)Pre-clinical

Leadership Team at MindWalk Holdings

DE
Dr. Evelyn Reed, Ph.D.
Chief Executive Officer
MT
Michael Thorne, MBA
Chief Financial Officer
DA
Dr. Aris Kellaris, M.D., Ph.D.
Chief Medical Officer
DP
David Park, J.D.
Chief Business Officer
RV
Robert Vance
Chairman of the Board
DL
Dr. Lisa Monroe, M.D.
Board Director
JF
James Fitzgerald
Board Director
DH
Dr. Henrik Jansen, Ph.D.
SVP, Head of Research
MR
Maria Rodriguez
VP, Clinical Operations
DT
Dr. Thomas Wright, Ph.D.
VP, Preclinical Development
View full MindWalk Holdings profile